Clag-m/i方案治疗儿童复发/难治急性髓系白血病的临床疗效和安全性分析
WebDec 3, 2015 · The CLAG regimen (G-CSF 300 mcg sc, cladribine 5 mg/m 2 over 2 hours, and cytarabine 2 gm/m 2 over 4 hours beginning 2 hours after cladribine, all daily times 5 … WebCLAG-M is typically given to patients with relapsed or refractory AML after one or more prior treatments. The goal of CLAG-M is to eliminate leukemia cells from the body and to …
Clag-m/i方案治疗儿童复发/难治急性髓系白血病的临床疗效和安全性分析
Did you know?
WebNov 3, 2024 · ORR of 83% at the recommended Phase 2 dose of 0.75uCi/kg of Actimab-A with CLAG-M; Actimab-A CLAG-M combo was active in patients with TP53 mutations with an ORR of 73% and an ORR of 55% in ... Web使用clag-m/i方案1个疗程后，6例患儿cr；1例患儿pr，接受了第2个疗程治疗，并最终获得cr；7例cr患儿后续均进行了allo-hsct。 截至末次随访时间，7例患儿处于CR状态，例8 …
WebCladribine is used to treat hairy cell leukemia, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphomas. Cladribine is administered by infusion through a vein. The … http://www.qk.sjtu.edu.cn/jimcp/CN/Y2024/V14/I02/116
WebMay 2, 2024 · One such regimen is CLAG-M (Cladribine, Cytarabine, Mitoxantrone, G-CSF) that has been frequently used at our center. However, it is difficult to predict which patients are likely to respond to CLAG-M or experience treatment-related toxicities. In patients with newly diagnosed AML, studies have demonstrated that achievement of minimal residual ... WebIn our comparisons, we included 51 patients treated with CLAG-M with mitoxantrone at 16 mg/m (40 on-study patients treated at the RP2D and 11 patients treated off-protocol) and 30 patients treated with CLAG-M with mitoxantrone at 10 mg/m (all off-study), who all met the medical criteria for enrollment in our phase I/II study (i.e., treatment ...
WebNov 5, 2024 · We conclude that lintuzumab Ac225 in combination with CLAG-M chemotherapy has a clinically acceptable safety profile. Dose escalation yielded highly encouraging efficacy results for RR-AML. With acceptable safety at 0.75uCi/kg, we have amended this protocol to study a 4 th dose level at 1.0uCi/kg. Overall, this regimen …
http://www.qk.sjtu.edu.cn/jimcp/CN/Y2024/V14/I02/116 dave meadows yorkWebIn case of partial remission, a second CLAG-M was administered. Patients in complete remission (CR) received consolidation courses based on high-dose Ara-C and MIT with or without 2-CdA. Forty-three patients from five centers were registered: 25 primary resistant and 18 relapsed. CR was achieved in 21 (49%) patients, 20 (47%) were refractory ... dave mearns and brian thorneWeb最终选入5篇文献进行分析,CR率在34.6%～78.8%之间,加上本研究7例患者共104例, CR患者为61例。. 结论:CLAG方案对难治、复发AML有效,化疗所致骨髓抑制较重,但安全性良好, … dave mearns booksWebAug 22, 2024 · Patients who do not achieve CR after two induction courses will be randomized to one of the standard salvage regimens (FLAG-IDA or CLAG-M). Postremission treatment intensity will be adjusted to risk group based on cytogenetic and molecular risk factors at diagnosis and AML biology (secondary AML, therapy related AML). dave mearns person centred counsellingWebSixty-six patients (58%) achieved CR after one or two courses of CLAG-M, 49 (35%) were refractory, and 8 (7%) died early. WBC >10 g/L and age >34 yr were factors associated with increased risk of treatment failure. Hematological toxicity was the most prominent toxicity of this regimen. The probability of OS at 4 yr was 14% (95% CI 4-23%). dave mearns wikipediaWebMay 29, 2024 · Three of the 10 trials use the cladribine or cladribine-base treatment protocol.11,17,21 The remaining seven trials used CLAG or CLAG-based treatment protocol, of which three trials were standard CLAG chemotherapy (2-CdA 5 mg/m 2 iv d1–5, Ara-C 2 g/m 2 iv d1–5, G-CSF 300 µg sc d0–5).12–14 And the other four trials were CLAG in a ... dave mears facebookWebIn collaboration with the Medical College of Wisconsin, the Actimab-A + CLAG-M Phase 1 trial was conducted in high-risk, r/r AML patients with a median age of 63 who had failed two or more lines of therapy, had adverse cytogenetics (i.e., 67% had adverse cytogenetics with 52% having a TP53 mutation associated with very poor outcomes) or failed ... dave mearns counselling